Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
113 hedge funds and large institutions have $112M invested in Cymabay Therapeutics in 2019 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 46 closing their positions.
1,591% more call options, than puts
Call options by funds: $930K | Put options by funds: $55K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
10% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 31
18% less funds holding
Funds holding: 137 → 113 (-24)
41% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 46
66% less capital invested
Capital invested by funds: $328M → $112M (-$216M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Engine Capital Management
New York
|
+$18.7M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$10.5M |
| 3 |
Morgan Stanley
New York
|
+$7.54M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.99M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$3.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$29.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.2M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$12M |
| 4 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$10.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.5M |
CBAY Hedge Fund Activity: Q4 2019 in Review
113 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2019, worth a combined $112M — down 66% from $328M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of CBAY and 27 opened new positions — a net loss of 19 holders — while 31 trimmed existing stakes and 34 added.
The largest buyer was Engine Capital Management, opening a new position worth an estimated $18.7M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $29.2M sold.
- 113 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2019, down from 137 in Q3 2019.
- Funds reported $112M of Cymabay Therapeutics stock for Q4 2019, down 66% quarter-over-quarter.
- 27 funds opened new Cymabay Therapeutics positions in Q4 2019 and 46 closed out, a net change of -19 holders.
- The largest Cymabay Therapeutics buyer in Q4 2019 was Engine Capital Management, an estimated $18.7M added.
- The largest Cymabay Therapeutics seller in Q4 2019 was Baker Bros. Advisors, an estimated $29.2M sold.
Based on aggregated 13F filings for Q4 2019.